J Vetsch1,2, C E Wakefield1,2, E G Robertson1,2, T N Trahair1,2, M K Mateos1,2, M Grootenhuis3,4, G M Marshall1,2, R J Cohn1,2, J E Fardell5,6. 1. School of Women's and Children's Health, UNSW, Sydney, Australia. 2. Kids Cancer Centre, Sydney Children's Hospital, High Street, Randwick, NSW, 2031, Australia. 3. Psychosocial Department Emma Children's Hospital AMC, Amsterdam, The Netherlands. 4. Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands. 5. School of Women's and Children's Health, UNSW, Sydney, Australia. j.fardell@unsw.edu.au. 6. Kids Cancer Centre, Sydney Children's Hospital, High Street, Randwick, NSW, 2031, Australia. j.fardell@unsw.edu.au.
Abstract
PURPOSE: Acute lymphoblastic leukemia (ALL) survivors are the largest group of childhood cancer survivors; however, their risk for late effects is high. Cancer-related late effects have the potential to compromise health-related quality of life (HRQL) long into survivorship. None of the reviews so far have focused on ALL solely, but described HRQL for all childhood cancers. We aimed to identify ALL survivors at risk for poor HRQL and identify possible risk factors. METHOD: Following PRISMA guidelines, we performed a systematic review, searching published literature in Pubmed, PsycInfo, Embase, and the Cochrane database including all publications up to December 16, 2016. Two independent reviewers (JV and ER) screened eligible articles and assessed article quality. RESULTS: We found 31 studies representing 4356 survivors and 901 proxies. Thirteen studies found worse, eight found no difference, and three better, overall HRQL scores compared with healthy controls or norms. ALL survivors typically had better overall HRQL scores than survivors of other childhood cancers. Clinical variables (e.g., treatment received) were not consistently associated with HRQL; however, experiencing worse late effects was associated with lower HRQL. Survivor and parent socio-demographic factors and psychological factors such as resilience and depression were also associated with HRQL. CONCLUSION: ALL survivors appeared to have worse or equivalent HRQL compared with controls, but better HRQL than survivors of other cancer types. However, studies reported a wide variability in HRQL and potential risk factors for poor HRQL. Measuring ALL survivors' HRQL longitudinally and comprehensively assessing potential risk factors might identify future avenues to intervene early.
PURPOSE:Acute lymphoblastic leukemia (ALL) survivors are the largest group of childhood cancer survivors; however, their risk for late effects is high. Cancer-related late effects have the potential to compromise health-related quality of life (HRQL) long into survivorship. None of the reviews so far have focused on ALL solely, but described HRQL for all childhood cancers. We aimed to identify ALL survivors at risk for poor HRQL and identify possible risk factors. METHOD: Following PRISMA guidelines, we performed a systematic review, searching published literature in Pubmed, PsycInfo, Embase, and the Cochrane database including all publications up to December 16, 2016. Two independent reviewers (JV and ER) screened eligible articles and assessed article quality. RESULTS: We found 31 studies representing 4356 survivors and 901 proxies. Thirteen studies found worse, eight found no difference, and three better, overall HRQL scores compared with healthy controls or norms. ALL survivors typically had better overall HRQL scores than survivors of other childhood cancers. Clinical variables (e.g., treatment received) were not consistently associated with HRQL; however, experiencing worse late effects was associated with lower HRQL. Survivor and parent socio-demographic factors and psychological factors such as resilience and depression were also associated with HRQL. CONCLUSION: ALL survivors appeared to have worse or equivalent HRQL compared with controls, but better HRQL than survivors of other cancer types. However, studies reported a wide variability in HRQL and potential risk factors for poor HRQL. Measuring ALL survivors' HRQL longitudinally and comprehensively assessing potential risk factors might identify future avenues to intervene early.
Authors: Wendy Demark-Wahnefried; Cary Werner; Elizabeth C Clipp; Ann Bebe Guill; Melanie Bonner; Lee W Jones; Philip M Rosoff Journal: Cancer Date: 2005-05-15 Impact factor: 6.860
Authors: Lauren M Touyz; Jennifer Cohen; Kristen A Neville; Claire E Wakefield; Sarah P Garnett; Kylie-Ann Mallitt; Allison M Grech; Richard J Cohn Journal: Pediatr Blood Cancer Date: 2016-11-10 Impact factor: 3.167
Authors: Sophia Colombari Figueroa; Chris J Kennedy; Catharina Wesseling; Joseph M Wiemels; Libby Morimoto; Ana M Mora Journal: Environ Res Date: 2019-12-10 Impact factor: 6.498
Authors: Andrew Garas; Louise A McLean; Cinzia R De Luca; Peter Downie; Maria C McCarthy Journal: Support Care Cancer Date: 2019-03-21 Impact factor: 3.603
Authors: Ellen van der Plas; T Leigh Spencer Noakes; Darci T Butcher; Rosanna Weksberg; Laura Galin-Corini; Elizabeth A Wanstall; Patrick Te; Laura Hopf; Sharon Guger; Johann Hitzler; Russell J Schachar; Shinya Ito; Brian J Nieman Journal: Pediatr Res Date: 2020-11-17 Impact factor: 3.953
Authors: Liv Andrés-Jensen; Mette Tiedemann Skipper; Kristian Mielke Christensen; Pia Hedegaard Johnsen; Katrine Aagaard Myhr; Martin Kaj Fridh; Kathrine Grell; A M L Pedersen; Sune Leisgaard Mørck Rubak; Martin Ballegaard; Arne Hørlyck; Rikke Beck Jensen; Trine-Lise Lambine; Kim Gjerum Nielsen; Ruta Tuckuviene; Peder Skov Wehner; Birgitte Klug Albertsen; Kjeld Schmiegelow; Thomas Leth Frandsen Journal: BMJ Open Date: 2021-02-09 Impact factor: 2.692
Authors: Sascha Lieber; Victoria Ruscher; Jörn-Sven Kühl; Johannes Schulte; Markus Blankenburg; Tobias Reindl; Pablo Hernáiz Driever Journal: J Cancer Res Clin Oncol Date: 2020-04-28 Impact factor: 4.553